WROCŁAW, Poland, Nov. 25, 2022 (GLOBE NEWSWIRE) -- Captor Therapeutics S.A. (WSE:CTX), a biopharmaceutical company dedicated to the development of Targeted Protein Degradation (TPD)-based drugs for ...
WROCŁAW, Poland, March 07, 2023 (GLOBE NEWSWIRE) -- Captor Therapeutics S.A. (“Captor”) (WSE:CTX), a leader in the development of Targeted Protein Degradation (TPD)-based drugs, today announced its ...
Captor Therapeutics Inc. has disclosed molecular glue degraders comprising a cereblon (CRBN) binding moiety acting as serine/threonine-protein kinase Nek7 degradation inducers reported to be useful ...
Strong preclinical data generated with CT-02 against NEK7 CT-05 potential best-in-class profile in high potential / partially de-risked PKCӨ protein pathway Webcast to take place on Thursday 30 th ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results